DeutschNewstral
Article
jdsupra.com on 2021-02-01 21:52
FDA Accepts Bio-Thera Solutions’ Biologics License Application for BAT1706, a Proposed Biosimilar to Avastin®
Related news
- First Patient Dosed with Stelara® biosimilar in Bio-Thera Solutions’ Phase III Clinical Trial for Moderate to Severe Psoriasisjdsupra.com
- Bio-Thera Solutions and Hikma Pharmaceuticals Enters Into Ustekinumab Biosimilar Agreementjdsupra.com
- FDA Approves First Avastin Biosimilarjdsupra.com
- Celltrion Seeks EMA Approval for Avastin Biosimilarjdsupra.com
- FDA Approves Amgen’s Biosimilar of Avastin®jdsupra.com
- Amgen and Allergan Submit European Application for Avastin® Biosimilarjdsupra.com
- Genentech Files DJ Action Against Amgen Regarding Avastin Biosimilarjdsupra.com
- Amgen and Genentech Break New Ground in Avastin Biosimilar Disputejdsupra.com
- Amgen and Allergan Submit BLA for Avastin® Biosimilarjdsupra.com
- Amgen Reports on Neulasta, Neupogen Biosimilar Competition and Acceptance of Avastin Biosimilar aBLAjdsupra.com
- Biosimilar Market Updates: Samsung Biologics, Celltrion, and Alvotechjdsupra.com
- Deal news: Bio-Thera Solutions and Intract Pharmajdsupra.com
- FDA Accepts Coherus’s aBLA for Neulasta® Biosimilarjdsupra.com
- FDA Accepts Samsung Bioepis’s Bevacizumab Biosimilar (SB8)jdsupra.com
- FDA Accepts Mylan aBLA or Pegfilgrastim Biosimilarjdsupra.com
- FDA accepts Coherus’s resubmitted pegfilgrastim biosimilar applicationjdsupra.com
- No Declaratory Judgment Jurisdiction in Dispute Over Avastin® Biosimilar Launch Date; Questions Remainjdsupra.com
- MAmgen and Allergan say FDA has approved biosimilar of Roche's Avastinmarketwatch.com
- Biogen and Bio-Thera Solutions Announce Collaboration on Proposed Actemra® (Tocilizumab) Biosimilarjdsupra.com
- Bio-Thera Solutions Announces Initiation of Phase III Clinical Trial for Tocilizumab Biosimilarjdsupra.com